Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development

Bay-Jensen, Anne-Christine, Thudium, Christian S, Gualillo, Oreste and Mobasheri, Ali (2017) Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development Drug Discovery Today, 23 (2). pp. 349-358.

Text ECM markers for drug development in OA_Clean_SEP2017.docx - Accepted version Manuscript Download (290kB)

Abstract

Osteoarthritis (OA) is the most common form of joint disease. This presents the OA research community and pharmaceutical companies developing disease-modifying osteoarthritis drugs (DMOADs) with great opportunities.. The different OA subtypes complicates the traditional approaches for developing new treatments. If we can identify new markers that can distinguish different subtypes this can greatly facilitate drug development from early discovery to late clinical development. Nevertheless, the current approaches result in poorly targeted treatments and the inability to recruit the right patients for clinical trials. Thus, there is an urgent medical need for objective biomarker tools for patient phenotyping.

Item Type:	Article
Divisions :	Faculty of Health and Medical Sciences > School of Veterinary Medicine
Authors :	Name Email ORCID Bay-Jensen, Anne-Christine Thudium, Christian S Gualillo, Oreste Mobasheri, Ali a.mobasheri@surrey.ac.uk
Date :	14 October 2017
DOI :	10.1016/j.drudis.2017.10.008
Copyright Disclaimer :	© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Uncontrolled Keywords :	Drug discovery; osteoarthritis; cartilage; synovium; biomarker; biochemical marker
Depositing User :	Jane Hindle
Date Deposited :	17 Oct 2017 14:01
Last Modified :	14 Oct 2018 02:08
URI:	http://epubs.surrey.ac.uk/id/eprint/842556

Actions (login required)

View Item

Downloads